Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Sander

Showing results (171-180 of 233) with videos related to

Pageof 24
Sort By:
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
Nature Methods|July 1, 2015
Pathway and network analysis of cancer genomesPau Creixell, Jüri Reimand, Syed Haider, et al.
Bioinformatics (Oxford, England)|April 15, 2003
Evaluation of annotation strategies using an entire genome sequenceIoannis Iliopoulos, Sophia Tsoka, Miguel A Andrade, et al.
Cancer Cell|December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancerLianjie Li, Chuan Shen, Eijiro Nakamura, et al.
Plos One|July 11, 2014
Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphomaJustin Rendleman, Yevgeniy Antipin, Boris Reva, et al.
Cancer Cell|January 15, 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell CarcinomaA Ari Hakimi, Ed Reznik, Chung-Han Lee, et al.
Nature|October 23, 2014
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficileCharlie G Buffie, Vanni Bucci, Richard R Stein, et al.
Nature Genetics|December 1, 2009
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah, Barry S Taylor, Shasha Meng, et al.
Cancer Cell|August 16, 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progressionMuhan Chen, Christopher P Pratt, Martha E Zeeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Pageof 24

Showing results (171-180 of 233) with videos related to

Sort By:
Pageof 24
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
Nature Methods|July 1, 2015
Pathway and network analysis of cancer genomesPau Creixell, Jüri Reimand, Syed Haider, et al.
Bioinformatics (Oxford, England)|April 15, 2003
Evaluation of annotation strategies using an entire genome sequenceIoannis Iliopoulos, Sophia Tsoka, Miguel A Andrade, et al.
Cancer Cell|December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancerLianjie Li, Chuan Shen, Eijiro Nakamura, et al.
Plos One|July 11, 2014
Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphomaJustin Rendleman, Yevgeniy Antipin, Boris Reva, et al.
Cancer Cell|January 15, 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell CarcinomaA Ari Hakimi, Ed Reznik, Chung-Han Lee, et al.
Nature|October 23, 2014
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficileCharlie G Buffie, Vanni Bucci, Richard R Stein, et al.
Nature Genetics|December 1, 2009
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah, Barry S Taylor, Shasha Meng, et al.
Cancer Cell|August 16, 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progressionMuhan Chen, Christopher P Pratt, Martha E Zeeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Pageof 24